Flea and Tick Oral Prevention (Bravecto, NexGard, Simparica) — pet safety profile
Moderate riskOral flea and tick prevention medications in the isoxazoline class (afoxolaner/NexGard, fluralaner/Bravecto, sarolaner/Simparica).
What is this product?
Oral flea and tick prevention medications in the isoxazoline class (afoxolaner/NexGard, fluralaner/Bravecto, sarolaner/Simparica). FDA-approved with established efficacy. FDA issued 2018 alert regarding potential for neurological adverse events (seizures, ataxia, tremors) in some dogs, particularly those with seizure history.
What's in it
Click any compound name for its full safety profile, regulatory consensus, and exposure data.
Active Class Reference
Who's most at risk
- Children — Developing endocrine and neurological systems, higher exposure per body weight
Red flags — when to walk away
- Product not veterinarian-recommended or approved — Unverified safety and efficacy for intended use.
Green flags — what to look for
- NASC quality seal or veterinary recommendation — Third-party quality verification and professional endorsement.
Safer alternatives
- Topical flea/tick prevention — non-isoxazoline
- Flea/tick collar — seresto-type, non-oral route
- Environmental flea control as supplement to reduced medication — Safer option
Frequently asked questions
Who should be careful with Flea and Tick Oral Prevention (Bravecto, NexGard, Simparica)?
Vulnerable populations identified for this product type: children.
Are there safer alternatives to Flea and Tick Oral Prevention (Bravecto, NexGard, Simparica)?
Yes — consider: Topical flea/tick prevention; Flea/tick collar; Environmental flea control as supplement to reduced medication. See the Safer alternatives section above for details.
Look up Flea and Tick Oral Prevention (Bravecto, NexGard, Simparica) in the pets app
Search by ingredient, browse by category, or compare to alternatives in the live app.
Open in pets View raw API dataReference data, not professional advice. Aggregates publicly available regulatory and scientific information. Why we built ALETHEIA →